Navitor™ TAVI System

NAVITOR™
TAVI SYSTEM
TAVI

Stable delivery. Remarkable performance. Future ready.

ADVANCING THE FOREFRONT OF TAVI INNOVATION

The Navitor Transcatheter Aortic Valve Implantation (TAVI) System is at the cutting edge of minimally invasive heart valve replacement. Designed for stable delivery, remarkable performance, and future-ready capabilities, the Navitor TAVI System sets a new standard in the field of TAVI, which is also known as TAVR (Transcatheter Aortic Valve Replacement).

EXCELLENCE ELEVATED IN TAVI

The Navitor TAVI System is intuitive, precise, and accurate, offering excellent hemodynamics and durability for TAVI procedures. Its design ensures a seamless and optimized valve replacement experience, making it a preferred choice for clinicians and patients alike.

NAVITOR VISION^* VALVE FEATURES

Attention to every detail

The Navitor Vision Valve is engineered with meticulous attention to detail, ensuring optimal outcomes for TAVI procedures.

^*Labeled as Navitor and Navitor Titan with Vision Technology

EXCELLENT OUTCOMES IN CLINICAL TRIAL RESULTS | 30-DAY^1,2

DISCOVER FEATURES AND BENEFITS
OF THE NAVITOR™ TAVI SYSTEM.

FIND OUT MORE ABOUT:

AORTIC STENOSIS WATCH TAVI SUMMIT 2023

Connext
TV

CONNECT TO THE LATEST
IN STRUCTURAL HEART
THERAPY

Find out more

TV

EuroPCR 2023 - Learnings and perspectives from the COAPT trial, 5-year follow-up

EuroPCR 2023: COAPT 5-year follow-up

EuroPCR 2023: Learnings and perspectives from the COAPT trial, 5-year follow-up

TAVI Case-Club – Alternative access

TAVI Case Club – The real-world challenge of alternative access

TAVI 2023: The next level

TAVI 2023: How to drive TAVI to the next level – Future perspectives, key takeaways and closing remarks

TAVI 2023: Optimizing TAVI

TAVI 2023: Optimizing TAVI – A live demonstration

TAVI Summit 2023: Morphology

TAVI 2023: Procedural refinements – How to get the best from your procedures

TAVI 2023: Calcified valve

TAVI 2023: Procedural refinements – Heavily calcified aortic valve

TAVI Summit 2023: Streamline implantation

TAVI 2023: Procedural refinements – Implantation of an intra-annular self-expanding THV

TAVI 2023: Younger patients

TAVI 2023: New indications and trends in TAVI – Younger patients

TAVI Summit 2023: AS with HF

TAVI 2023: New indications and trends in TAVI – Aortic Stenosis with heart failure

TAVI Summit 2023: Aortic stenosis

TAVI 2023: New indications and trends in TAVI – Asymptomatic aortic stenosis

References

Søndergaard L, Walton AS, Worthley SG, et al. Thirty-day and one-year outcomes of the Navitor transcatheter heart valve in patients with aortic stenosis: the prospective, multicentre, global PORTICO NG study. Eurointervention 2023;EIJ-D-22-01108. eurointervention.pcronline.com/article/thirty-day-and-one-year-outcomes-of-thenavitor-transcatheter-heart-valve-in-patients-with-aortic-stenosis-the-prospective-multicentre-global-portico-ng-study.
Søndergaard, L. 30-day outcomes from a next generation TAVI device with an active sealing cuff. Presented at: EuroPCR conference; May 18–20, 2021.
Pibarot P, Hahn RT, Weissman NJ, et al. Assessment of paravalvular regurgitation following TAVR: a proposal of unifying grading scheme. JACC Cardiovasc Imaging. 2015;8(3):340–360.
doi.org/10.1016/j.jcmg.2015.01.008.
Frater RWM, Seifter E, Liao K, et al. Advances in Anticalcific and Antidegenerative Treatment of Heart Valve Bioprostheses. Austin, TX: Silent Partners Inc; 1997:105–114.
Kelly SJ, Ogle, MF, Carlyle WC, et al. Biocompatibility and calcification of bioprosthetic heart valves. Society for biomaterials. Sixth World Biomaterials Congress Transaction. 2000;13534.
Vyavahare N, Hirsch D, Lerner E, et al. Prevention of bioprosthetic heart valve calcification by ethanol preincubation: efficacy and mechanisms. Circulation.
1997;95(2):479–488. doi.org/10.1161/01.CIR.95.2.479.
Vyavahare N, Hirsch D, Lerner E, et al. Prevention of calcification of glutaraldehyde-crosslinked porcine aortic cusps by ethanol preincubation: mechanistic studies of protein structure and water-biomaterial relationships. J Biomed Mater Res. 1998;40(4):577–585.https://doi.org/10.1002/(SICI)1097-4636(19980615)40:4%3C577::AID-JBM9%3E3.0.CO;2-C.
Gross JM. Calcification of bioprosthetic heart valves and its assessment. J Thorac Cardiovasc Surg. 2003;125:S6–8. doi.org/10.1067/mtc.2003.208.
Tod TJ, Dove JS. The association of bound aldehyde content with bioprosthetic tissue calcification. J Mater Sci: Mater Med. 2016;27:8.
doi.org/10.1007/s10856-015-5623-z.
Meuris B, De Praetere H, Strasly M, et al. A novel tissue treatment to reduce mineralization of bovine pericardial heart valves. JTCVS. 2018;156(1):197–206. doi.org/10.1016/j.jtcvs.2018.01.099.
Data on file at Abbott. 90664679
Medtronic CoreValve Evolut^‡ PRO Instructions for Use.
Navitor™ TAVI System Instructions for Use.
Boston Scientific ACURATE neo2^‡ Instructions for Use.
Boston Scientific iSleeve^‡ Instructions for Use.
Edwards Sapien^‡ 3 Instructions for Use.
Koehler Sapien^‡ 3 eSheath OD BMRI 2015.
Abbott data on file 90368819.
Abbott data on file 90346620.
Portico™ TAVI System Instructions for Use

^‡Indicates a third-party trademark, which is the property of its respective owner.

Caution: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available)or at eifu.abbottvascular.com or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions.

Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.